Dr. Marty Makary will testify before the Senate health committee on Thursday. Lawmakers may press him over staff reductions and changes in agency direction on issues like vaccines.

A team of German scientists and biotech company Dynamic42 have jointly developed a ‘tumour-on-chip’ model of pancreatic ductal adenocarcinoma (PDAC), allowing insights into interactions between tumour cells and potential treatments.

A new assay rapidly detected pancreatic ductal adenocarcinoma and differentiated it from noncancer pancreatic diseases by measuring cancer-associated protease activity in a small amount of blood.

The biotech company Dynamic42, a specialist in organ-on-chip technology, has made a significant advance in pancreatic cancer drug research in collaboration with the research team of Prof. Dr. Nicole Teusch at the Institute of Pharmaceutical Biology and Biotechnology at Heinrich Heine University Düsseldorf.

Pancreatic cancer remains difficult to treat, and is responsible for around 8 percent of all cancer deaths.It also has one of the lower longterm survival rates with only about 13 percent of patients surviving more than five years.

ImmunityBio shares advanced 17% to $3.34 after the company said the Food and Drug Administration awarded a regenerative medicine advanced therapy designation for Anktiva and CAR-NK for the reversal of lymphopenia in patients receiving standard-of-care chemotherapy/radiotherapy.

Unlike chemotherapy with its known toxicity towards normal body systems, Namodenoson provides protective effectsRamat Gan, Israel, March 03,

TNG462 granted Orphan Drug Designation for treatment of pancreatic cancer –– Investigational New Drug (IND) application for TNG456, a